Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR

Core Viewpoint - The U.S. District Court has denied the FTC's request for a preliminary injunction to block the proposed acquisition of Surmodics by GTCR, marking a significant step towards the completion of the merger [1][3]. Group 1: Merger Details - The consummation of the merger is still subject to a Temporary Restraining Order, which prevents the parties from finalizing the merger before 5:00 p.m. Central time on November 17 [2]. - The merger agreement includes conditions such as the absence of any legal restraints, no material adverse effect on the company, and other customary closing conditions [2]. Group 2: Company Background - Surmodics is a leading provider of medical device and in vitro diagnostic technologies, focusing on performance coating technologies for intravascular medical devices and components for diagnostic tests [4]. - The company's mission is to improve disease detection and treatment, leveraging its expertise in surface modification and drug-delivery coating technologies [4].